ARUP Launches First Clinical Spectral Flow Cytometry Assay for MRD Assessment in Multiple Myeloma

Summary

ARUP Laboratories announced the launch of ARUP CLARISPECT™, a new clinical spectral flow cytometry assay for minimal residual disease (MRD) assessment in multiple myeloma patients. The assay aims to detect small neoplastic populations with greater sensitivity than conventional flow cytometry methods.